Question for you. With Vyvanse on limited supply, is that so we don't run out? And how does that impact the quarter 1 numbers? I'm seeing a lot of higher numbers projected but I tend to be more cautious. What are you basing the 40 and potential 50 mil/quarters on? Is that more opinion or was there something I missed in the CC? Thanks in advance for your insight.
Market Data 
Markets 
